Synthetic, Thymus-like 3D Niche for T Cell Generation from Stem Cells

用于从干细胞生成 T 细胞的合成类胸腺 3D 生态位

基本信息

  • 批准号:
    8051730
  • 负责人:
  • 金额:
    $ 21.37万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-04-01 至 2013-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): It is now well established in the T cell development literature that two key signals, presented in the thymic niche, in a highly controlled and sequential manner, play crucial roles in generating functional T cells: (i) Delta like ligands - Notch receptor signaling and (ii) Major Histocompatibility Complex (MHC) - T cell receptor (TcR) signaling. The Delta like ligands that control Notch signaling and the MHC molecules that direct TcR signaling in the thymus are present on the surface of stromal cells and antigen presenting cells, with which the developing stem/progenitor cells directly interact. It has been shown that at least the Notch signaling process can be mimicked in vitro using retrovirally transfected stromal cells displaying Notch ligands. Recently, we have reported that microbeads with surface-immobilized Notch ligands (delta-like ligand 4, DLL4) can efficiently direct hematopoietic progenitor cells to the early T cell lineage. In addition, we have now demonstrated that, using a combination of surface-immobilized Notch ligand-mediated signaling and exogenous, soluble antigen-loaded MHC tetramer-mediated TcR signaling, both mouse embryonic stem (ES) cells and mouse induced pluripotent stem (iPS) cells can be directed to the T cell pathway and differentiated into functional, CD8+ T cells specific for the same antigen. However, most efforts to date, including our own has focused on mimicking these niche-specific signals in 2D environments. Based on our promising data in these 2D systems, we hypothesize that a 3D tissue-like microenvironment that can efficiently trigger Delta- Notch and MHC-TcR signaling pathways in cultured ES or iPS cells would provide significant improvement in the efficiency of T cell generation. Our goal here is to engineer such synthetic, 3D T cell niches (artificial thymus-like microenvironment) to direct pluripotent stem cells into therapeutic, antigen-specific T cells. The specific aims of this exploratory research are: Aim 1: To develop and characterize inverse opal hydrogel scaffolds functionalized with ligands essential for T cell differentiation. Aim 2: To efficiently differentiate mouse ES and iPS cells into early T cells using Notch ligand-functionalized inverse opal hydrogel scaffolds. Aim 3: To efficiently generate antigen-specific, functional CD8+ T cells from the early T cell population obtained in Aim 2, using antigen-loaded, MHC-functionalized inverse opal hydrogels and evaluate their antigen specificity and cross-reactivity to self antigens. PUBLIC HEALTH RELEVANCE: The goal of this two year exploratory project is to develop a three dimensional thymus- like microenvironment to generate functional, antigen-specific T cells from mouse embryonic or induced pluripotent stem cells. Our approach is to mimic the thymic niche by creating scaffolds that present specific T cell differentiation signals in an efficient manner. If successful this could lead to adoptive T cell therapy using stem cell derived cells.
描述(由申请人提供):目前在T细胞发育文献中已充分确立,以高度受控和顺序的方式存在于胸腺小生境中的两种关键信号在产生功能性T细胞中起关键作用:(i)δ样配体- Notch受体信号传导和(ii)主要组织相容性复合体(MHC)- T细胞受体(TcR)信号传导。在胸腺中控制Notch信号传导的Delta样配体和指导TcR信号传导的MHC分子存在于基质细胞和抗原呈递细胞的表面上,发育中的干细胞/祖细胞与其直接相互作用。已经显示,至少Notch信号传导过程可以使用展示Notch配体的逆转录病毒转染的基质细胞在体外模拟。最近,我们报道了具有表面固定的Notch配体(δ样配体4,DLL 4)的微珠可以有效地将造血祖细胞引导至早期T细胞谱系。此外,我们现在已经证明,使用表面固定的Notch配体介导的信号传导和外源性可溶性抗原负载的MHC四聚体介导的TcR信号传导的组合,小鼠胚胎干细胞(ES)和小鼠诱导多能干细胞(iPS)细胞可以被引导至T细胞途径并分化为对相同抗原特异性的功能性CD 8 + T细胞。然而,迄今为止,包括我们自己在内的大多数努力都集中在模拟2D环境中的这些特定于利基的信号。基于我们在这些2D系统中的有希望的数据,我们假设可以在培养的ES或iPS细胞中有效触发Delta-Notch和MHC-TcR信号传导途径的3D组织样微环境将提供T细胞生成效率的显著改善。我们的目标是设计这种合成的3D T细胞小生境(人工胸腺样微环境),将多能干细胞定向为治疗性抗原特异性T细胞。本探索性研究的具体目标是:目的1:开发和表征反蛋白石水凝胶支架功能化与T细胞分化所必需的配体。目的2:利用Notch配体功能化的反蛋白石水凝胶支架有效地将小鼠ES和iPS细胞分化为早期T细胞。目标3:为了使用负载抗原的MHC功能化反蛋白石水凝胶从目标2中获得的早期T细胞群有效地产生抗原特异性功能性CD 8 + T细胞,并评估其抗原特异性和对自身抗原的交叉反应性。 公共卫生关系:这个为期两年的探索性项目的目标是开发三维胸腺样微环境,以从小鼠胚胎或诱导多能干细胞产生功能性抗原特异性T细胞。我们的方法是通过创建以有效方式呈现特异性T细胞分化信号的支架来模拟胸腺小生境。如果成功,这可能导致使用干细胞衍生细胞的过继性T细胞疗法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

KRISHNENDU ROY其他文献

KRISHNENDU ROY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('KRISHNENDU ROY', 18)}}的其他基金

Synthetic Nanoparticle-antibody (SNAb) Based Depletion of Myeloid-Derived Suppressor Cells for TB Host-Directed Therapy
基于合成纳米颗粒抗体 (SNAb) 的骨髓源性抑制细胞耗竭,用于结核宿主定向治疗
  • 批准号:
    10890900
  • 财政年份:
    2021
  • 资助金额:
    $ 21.37万
  • 项目类别:
Synthetic Nanoparticle-antibody (SNAb) Based Depletion of Myeloid-Derived Suppressor Cells for TB Host-Directed Therapy
基于合成纳米颗粒抗体 (SNAb) 的骨髓源性抑制细胞耗竭,用于结核宿主定向治疗
  • 批准号:
    10462723
  • 财政年份:
    2021
  • 资助金额:
    $ 21.37万
  • 项目类别:
Synthetic Nanoparticle-antibody (SNAb) Based Depletion of Myeloid-Derived Suppressor Cells for TB Host-Directed Therapy
基于合成纳米颗粒抗体 (SNAb) 的骨髓源性抑制细胞耗竭,用于结核宿主定向治疗
  • 批准号:
    10673996
  • 财政年份:
    2021
  • 资助金额:
    $ 21.37万
  • 项目类别:
Synthetic Nanoparticle-antibody (SNAb) Based Depletion of Myeloid-Derived Suppressor Cells for TB Host-Directed Therapy
基于合成纳米颗粒抗体 (SNAb) 的骨髓源性抑制细胞耗竭,用于结核宿主定向治疗
  • 批准号:
    10327084
  • 财政年份:
    2021
  • 资助金额:
    $ 21.37万
  • 项目类别:
Effect of presentation methods on the molecular mechanism of combinatorial adjuvants
呈现方法对组合佐剂分子机制的影响
  • 批准号:
    9882950
  • 财政年份:
    2016
  • 资助金额:
    $ 21.37万
  • 项目类别:
Synthetic, Thymus-like 3D Niche for T Cell Generation from Stem Cells
用于从干细胞生成 T 细胞的合成类胸腺 3D 生态位
  • 批准号:
    7874375
  • 财政年份:
    2010
  • 资助金额:
    $ 21.37万
  • 项目类别:
Generation of therapeutic T cells from cord blood-derived stem cells
从脐带血干细胞生成治疗性 T 细胞
  • 批准号:
    7633360
  • 财政年份:
    2008
  • 资助金额:
    $ 21.37万
  • 项目类别:
Generation of therapeutic T cells from cord blood-derived stem cells
从脐带血干细胞生成治疗性 T 细胞
  • 批准号:
    7471889
  • 财政年份:
    2008
  • 资助金额:
    $ 21.37万
  • 项目类别:
Shape Specific, Enzyme-Responsive, Nano-Imprinted Particles for Drug Delivery
用于药物输送的形状特定、酶响应、纳米压印颗粒
  • 批准号:
    7644354
  • 财政年份:
    2008
  • 资助金额:
    $ 21.37万
  • 项目类别:
Shape Specific, Enzyme-Responsive, Nano-Imprinted Particles for Drug Delivery
用于药物输送的形状特定、酶响应、纳米压印颗粒
  • 批准号:
    7511963
  • 财政年份:
    2008
  • 资助金额:
    $ 21.37万
  • 项目类别:

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 21.37万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 21.37万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10387023
  • 财政年份:
    2022
  • 资助金额:
    $ 21.37万
  • 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10248409
  • 财政年份:
    2019
  • 资助金额:
    $ 21.37万
  • 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
  • 批准号:
    nhmrc : GNT1163111
  • 财政年份:
    2019
  • 资助金额:
    $ 21.37万
  • 项目类别:
    Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10462684
  • 财政年份:
    2019
  • 资助金额:
    $ 21.37万
  • 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
  • 批准号:
    398018062
  • 财政年份:
    2018
  • 资助金额:
    $ 21.37万
  • 项目类别:
    Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9308643
  • 财政年份:
    2017
  • 资助金额:
    $ 21.37万
  • 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9447149
  • 财政年份:
    2017
  • 资助金额:
    $ 21.37万
  • 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
  • 批准号:
    8893915
  • 财政年份:
    2014
  • 资助金额:
    $ 21.37万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了